pre-IPO PHARMA

COMPANY OVERVIEW

NFlection Therapeutics focuses on the discovery and development of effective, targeted therapies for rare disorders. NFlection is chiefly concerned with rare disorders known as RASopathies, which are driven by the aberrant activation of the Ras/Raf/MEK/ERK pathway. NFlection is working to address RASopathies through the development of first-in-class soft MEK (mitogen-activated protein kinase kinase) inhibitors as topical treatments to mitigate or treat cutaneous neurofibromas in neurofibromatosis type 1, congenital birthmarks and immunosuppressant-mediated squamous cell carcinoma. NFlection’s topical MEK inhibitors are designed to degrade rapidly in circulation to avoid systemic side effects.


LOCATION

  • Wayne, PA, USA

  • THERAPEUTIC AREAS

  • Oncology
  • Rare Diseases

  • WEBSITE

    www.nflectionrx.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    f-prime-capital-partners venbio


    PRESS RELEASES


    Oct 18, 2021

    NFlection Therapeutics Appoints William Hodder as CEO and Expands Leadership Team to Accelerate Development of Targeted Treatments for Rare Diseases


    May 26, 2021

    NFlection Therapeutics' NFX-179 Gel Demonstrates Safety and Significant Reduction in p-ERK, a Key Biomarker Driving Neurofibroma Tumor Growth, in Positive Data From a 28-Day Phase 2a Clinical Trial


    Jun 9, 2020

    NFlection Therapeutics Launches with $20M Series A Funding to Advance Lead Program in Neurofibromatosis


    For More Press Releases


    Google Analytics Alternative